Hospital M&A in Vietnam: Why Good Assets Fail to Close

Vietnam’s healthcare sector is drawing unprecedented demand and steady capital. Yet even well-run hospitals routinely fail to close. Lotus Venture’s analysis finds that nearly 30% of signed sale and purchase agreements in healthcare never reach completion — far higher than in industrial, consumer or logistics deals. What makes these transactions so prone to breaking down, and how can investors work through the structural obstacles that derail promising acquisitions?

The reasons rarely come down to a lack of interest or capital. Execution risk grows out of regulatory hurdles, incomplete disclosures and valuation misalignment — three sources of persistent friction between sellers and buyers. This piece walks through each one, and how the sharper buyers are getting past them.

Market potential meets execution risk

Vietnam’s hospital market sits at the intersection of powerful demographic and economic forces. Rising incomes and higher patient expectations have pushed projected private healthcare expenditure past US$23 billion in 2025. Against that backdrop, regional strategics and private equity funds keep scanning for acquisition opportunities in large urban centres and fast-growing provincial hubs.

That appetite shows in recent headline deals. A Southeast Asian healthcare conglomerate acquired a controlling interest in a major Ho Chi Minh City hospital for US$517 million, a measure of the premium international groups will pay for scalable assets with a strong brand. Smaller platform deals, particularly in secondary cities, are also attracting bidders who want to consolidate fragmented markets and lift service quality.

For all that momentum, hospital M&A runs into a paradox. For every transaction that closes, several fail before completion. Lotus Venture’s analysis shows that in Vietnam’s healthcare sector, nearly 30% of signed sale and purchase agreements never proceed to closing — substantially higher than in industrial, consumer or logistics deals. The cause is rarely missing capital or missing interest. It is execution risk.

Regulatory hurdles that stretch timelines

One of the most defining challenges in hospital M&A is the regulatory and licensing environment. The legal framework has evolved over the past decade, but approvals for foreign participation stay slow and unpredictable. Investors routinely underestimate how long it takes to secure licences and local endorsements.

The amended Law on Enterprises and its accompanying regulations require several levels of review. Even a minority-stake transaction can trigger scrutiny at the Ministry of Health, the local Department of Health and the investment licensing authorities. In one case, a reputable regional healthcare investor signed a binding term sheet to acquire a controlling stake in a provincial hospital. Technical diligence wrapped up within 60 days, yet the buyer met a chain of procedural delays, from public disclosure to local consultation to fresh clarifications, that stretched the timeline past twelve months. The deal lapsed when the seller declined to extend exclusivity.

This experience is not unusual. Healthcare approvals can run six to nine months under the best of circumstances. Each layer of review generates fresh document requests, forces data to be revalidated and can reopen commercial terms. Inconsistent readings among local authorities make planning harder still.

To contain the risk, successful acquirers invest early in regulatory mapping and scenario planning. They identify every licence that must transfer with the asset, clarify which thresholds trigger Ministry-level sign-off, and build a realistic timeline into the deal structure. None of this removes uncertainty, but it dampens the last-minute surprises that so often derail a transaction.

Valuation divergence and diligence friction

Even when the regulatory path is clear, valuation stays a recurring point of tension. Sellers of high-quality hospitals tend to benchmark expectations against regional multiples or recent landmark deals, even when their own facilities operate below that standard. Buyers, in turn, are more cautious about the durability of cash flows, capital expenditure needs and revenue recognition.

Take a recent attempt by an international health group to acquire a large urban hospital. The seller insisted on a valuation that reflected steady occupancy and high-margin procedures, but diligence revealed significant variability in patient throughput and limited insurance coverage among the core clientele. Both sides had agreed a headline price in principle, yet the buyer ultimately proposed a sizeable adjustment to account for the risks it had found. Unable to reconcile expectations, the negotiation collapsed.

Valuation disputes are often made worse by gaps in disclosure. Hospitals in Vietnam frequently keep partial records or rely on manual systems that make revenue hard to track comprehensively. Staffing arrangements may carry informal practices or contractual inconsistencies, leaving buyers exposed to liabilities after completion. Equipment registers can understate replacement costs or compliance requirements, widening the gap between perceived and actual asset value.

Working through this calls for disciplined diligence with the right financial and legal expertise behind it. More buyers now deploy health-specific operational consultants to validate capacity utilisation and compliance standards before signing. That extra layer gives a sharper basis for valuation and lends credibility to the adjustments raised in negotiation.

Deal structuring in a high-risk environment

With regulatory hurdles stacked on top of valuation gaps, deal structuring has become a critical lever in Vietnamese hospital M&A. Rather than rely on a simple share transfer, sophisticated investors now build conditionality and protection straight into the transaction documents.

One effective approach is the conditional sale and purchase agreement tied explicitly to regulatory milestones. These contracts can make completion subject to formal approval by designated authorities within a defined window. If approvals do not come through, the parties either extend the timeline or terminate without liability. The structure aligns expectations and cuts disputes over timing.

Earn-outs and deferred consideration are gaining ground too. Where revenue consistency is questionable, buyers increasingly defer part of the purchase price, linking payment to specified performance metrics over 12 to 24 months. Earn-outs can be contentious, but they are often the only practical way to bridge divergent valuations without abandoning the deal.

Escrow arrangements add another layer, holding funds until key closing conditions are met. In one recent example, buyer and seller agreed to place 15% of the transaction value in escrow pending the transfer of operating licences and confirmation of no undisclosed liabilities. The mechanism reassured both sides while keeping momentum toward completion.

Indemnities and local partner guarantees matter a great deal in healthcare deals. Sellers may be required to warrant the accuracy of their licences and financial records, with recourse provisions that extend beyond closing. For foreign investors less familiar with local compliance nuances, these protections are an essential safeguard against financial and reputational exposure.

A strategic approach for the years ahead

Vietnam’s hospital sector will stay one of the country’s most dynamic M&A segments. Rising consumer demand, demographic tailwinds and the government’s continued focus on healthcare infrastructure all point to durable deal pipelines. The same factors that make the sector attractive also make it complex. Regulatory friction, inconsistent disclosure and valuation divergence will keep testing even experienced investors.

For acquirers, success will hinge on early regulatory engagement, comprehensive diligence and flexible structuring. Those who fold all three into their approach stand a better chance of clearing the structural barriers that have stalled so many promising deals. Across multiple mandates, Lotus Venture has found that patient, disciplined execution remains the single most decisive factor in realising the sector’s potential.

Lotus Investment Group advises on cross-border M&A and FDI into Vietnam and Southeast Asia. If you are underwriting Vietnam exposure, get in touch.